Pfizer

PFE · NYSE · USD

$27.80−1.14%−$0.32

Close · October 2, 2026

At a glance

Revenue growth: −1.65%; 2025 vs 2024
Net income growth: −3.24%; 2025 vs 2024
Net margin: 12.4%; 2024: 12.6%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Income statement · Quarterly
Item	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023
Total revenue	15,034	14,451	17,557	16,654	14,653	13,715	17,763	17,702	13,283	14,878	14,569	13,492
Cost of revenue	3,655	3,407	5,065	3,979	3,501	2,592	6,513	4,873	2,768	3,036	1,066	8,905
Gross profit	11,379	11,044	12,492	12,675	11,152	11,123	11,250	12,829	10,515	11,842	13,503	4,587
Selling, general and administrative	3,257	2,840	3,735	3,085	3,294	2,910	4,744	3,114	3,559	3,348	4,128	3,112
Research and development	2,746	2,452	3,323	2,492	2,443	2,179	3,101	2,565	2,676	2,480	2,773	2,682
Operating income	4,191	4,569	4,204	5,875	4,204	4,823	2,046	5,838	2,973	4,706	5,335	-2,386
EBIT	4,191	4,569	4,204	5,875	4,204	4,823	2,046	5,838	2,973	4,706	5,335	-2,386
EBITDA	5,802	6,179	5,864	7,533	5,826	6,437	3,834	7,585	4,700	6,438	7,001	-831
Interest expense	667	668	711	652	654	654	739	783	778	790	688	695
Pre-tax income	-653	3,169	-1,642	3,334	3,044	2,784	-10.0	4,715	-103	3,421	-4,129	-3,352
Income tax	-407	461	-2.0	-216	141	-189	-421	234	-134	293	-795	-964
Net income	-248	2,687	-1,648	3,541	2,910	2,967	410	4,465	41.0	3,115	-3,369	-2,382
Net income to common shareholders	-248	2,687	-1,648	3,541	2,910	2,967	410	4,465	41.0	3,115	-3,369	-2,382
Basic EPS	-0.04	0.47	-0.29	0.62	0.51	0.52	0.07	0.79	0.01	0.55	-0.60	-0.42
Diluted EPS	-0.04	0.47	-0.29	0.62	0.51	0.52	0.07	0.79	0.01	0.55	-0.60	-0.42
Average shares (basic)	5,699	5,691	5,686	5,685	5,685	5,675	5,667	5,667	5,666	5,657	5,647	5,646
Average shares (diluted)	5,699	5,731	5,686	5,714	5,706	5,710	5,703	5,705	5,696	5,697	5,647	5,646
Dividend per share	0.43	0.43	0.86	0.43	0.43	0.43	0.84	0.42	0.42	0.42	0.41	0.41